Chengdu-listed Vaccine Firm Kanghua Bio Announces Strategic Acquisition by Shanghai Biopharma M&A Fund

On July 20, Chengdu Kanghua Biological Products Co., Ltd. (stock code: 300841.SZ), a listed company in the vaccine sector, released its latest announcement stating that the Shanghai Biopharmaceutical M&A Fund (hereinafter referred to as the “M&A Fund”) intends to acquire Kanghua Bio through an agreement-based transaction. It was disclosed that both parties will strengthen cooperation and share resources to explore synergistic opportunities for the vaccine industries in Shanghai and Chengdu, accelerate the layout of a diversified vaccine pipeline, and continuously build a vaccine ecosystem integrating mature products with R&D capabilities.

As a critical component in safeguarding public health security, the vaccine industry is characterized by high entry barriers, stringent regulation, and long development cycles, offering substantial market potential. Kanghua Biologicals, a leading domestic vaccine enterprise, was listed on the ChiNext Board of the Shenzhen Stock Exchange on June 16, 2020 (see:Kanghua Biologics Lists on the STAR Market; Freeze-Dried Human Rabies Vaccine Revenue Exceeds RMB 500 Million), its core product, the human diploid cell rabies vaccine, is a high-end domestically produced vaccine that has been safely used for over a decade, with a solid market foundation and nationwide channel coverage.

Kangh also boasts a robust global pipeline of innovative products,Representative Product: Recombinant Hexavalent Norovirus Vaccine Successfully Licensed for International Markets(See details:From China’s First to the World’s First: Kangh Leads the Domestic Vaccine Race with “Innovation + Global Expansion”). This strategic merger and acquisition aims to focus on key segments of the vaccine industry chain and enhance the overall strategic layout. Going forward, both parties will leverage Kangh’s mature products and pipeline, integrate the industrial advantages of Shanghai and Chengdu, and accelerate the development of a vaccine industry ecosystem.

This acquisition represents a significant step in continuing to drive the coordinated development of the biopharmaceutical industries in Shanghai and Chengdu. Following the acquisition, Kangh will fully leverage Shanghai’s advantages in high-end R&D resources, top-tier talent reserves, and global capital aggregation to further enhance its industrialization level, manufacturing capabilities, and market share. The acquisition fund will integrate various industrial resources to support Kangh in consolidating resources across Shanghai and Chengdu, connecting with Shanghai’s R&D and clinical networks, and jointly building a collaborative system spanning R&D and production, thereby accelerating the implementation of the entire “R&D–Clinical–Commercialization” industry chain.

“This is not a simple corporate acquisition, but rather a ‘chemical reaction’ of industrial upgrading.”Co-President of M&A Fund, Li Chenstated, “This is a typical merger and acquisition characterized by complementary strengths and resource empowerment. The Shanghai Biopharmaceutical M&A Fund has deep roots in the biopharmaceutical industry, with advantages in capital, R&D resources, international channels, and industrial synergy capabilities. Kangh boasts strengths in technology, products, manufacturing, and domestic distribution channels. This acquisition will achieve a multiplier effect where 1+1>2.”

As a key component of the Shanghai State-owned Assets Fund Matrix,The Shanghai Biopharmaceutical M&A Fund is managed by SIIC Capital, a subsidiary of the Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC Group).. The fund will take a holistic view of the development of Shanghai’s biopharmaceutical industry, balancing government guidance with industrial development needs. It will focus on strategies such as collaboration with leading “chain-master” enterprises, strengthening industrial clusters and building out supply chains, and empowering growth through asset restructuring. By employing market-oriented approaches—including capital injection, governance improvement, management enhancement, and mergers and acquisitions—the fund will provide comprehensive support to “chain-master” enterprises. Through strategic synergy and resource introduction, it aims to “build, supplement, and strengthen” supply chains, continuously contributing to the transformation and upgrading of industrial chains in specialized sectors.

Kanghua Biological is a biopharmaceutical enterprise engaged in the research and development, production, and sales of biological products. Established in 2004, the company is equipped with an animal testing center and GMP-compliant production workshops for bacterial and viral vaccines featuring advanced technological standards. Its current product portfolio includes the ACYW135 Group Meningococcal Polysaccharide Vaccine and the Freeze-Dried Rabies Vaccine for Human Use (Human Diploid Cell). Since its inception, the company has obtained GMP certification from the China Food and Drug Administration, undertaken several scientific and technological projects, and filed over one hundred patent applications for technological innovations.